Altimmune (NASDAQ:ALT) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock.

ALT has been the subject of a number of other reports. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective for the company. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.83.

Altimmune Trading Down 6.0 %

ALT stock opened at $5.61 on Tuesday. The stock has a 50-day moving average price of $6.42 and a two-hundred day moving average price of $7.10. The stock has a market cap of $432.05 million, a PE ratio of -3.62 and a beta of 0.87. Altimmune has a 1 year low of $5.14 and a 1 year high of $11.16.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. On average, analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In other news, CFO Gregory L. Weaver bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC acquired a new stake in Altimmune during the third quarter worth approximately $31,000. SBI Securities Co. Ltd. acquired a new stake in Altimmune during the fourth quarter worth approximately $45,000. Virtus ETF Advisers LLC acquired a new stake in Altimmune during the fourth quarter worth approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune during the fourth quarter worth approximately $72,000. Finally, Sunbelt Securities Inc. lifted its position in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after acquiring an additional 8,470 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.